This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BD's Latest Pen Needle Innovation Designed To Make Injections Easier For People With Diabetes

"Building on the introduction of BD's 4mm needle and 5-bevel PentaPoint Comfort design, we are confident that our new EasyFlow Technology will provide the most comfortable injection experience to help enable patients to adhere more easily to their therapy regimens and ultimately improve their outcomes," said Linda Tharby, President, BD Medical – Diabetes Care.

BD's steady pace of patient friendly enhancements has caught the attention of some important audiences. For example, BD Ultra-Fine Nano 4mm Pen Needles with EasyFlow Technology have earned the Arthritis Foundation Ease-of-Use Commendation, which recognizes products proven to make life easier for people who have arthritis and other physical limitations. Independently tested by experts and evaluated by people with arthritis, EasyFlow Technology was commended for ease of use when attaching, injecting, and dispensing medication on select insulin pens for people with dexterity challenges.

EasyFlow Technology is currently available in the U.S. and Canada on all BD Ultra-Fine Nano 4mm Pen Needles with PentaPoint Comfort and will be available in many European countries in the coming months. For more information on how EasyFlow Technology and other BD innovations can help improve outcomes for people with diabetes, visit www.bd.com/nano

About Diabetes Diabetes is a disease in which the body has a shortage of insulin or a decreased ability to use insulin, a hormone that allows glucose (sugar) to enter cells and be converted to energy. When diabetes is not controlled, glucose and fats remain in the blood and, over time, damage vital organs. Diabetes has become a national health concern in the United States, with an estimated 26 million people - 8.3 percent of the population - living with the disease. Of those people, an estimated 18.8 million have been diagnosed with diabetes, and another 7 million are thought to be undiagnosed. If current trends continue, as many as one in three U.S. adults will have diabetes by 2050.[3] The total annual cost of diagnosed diabetes in the United States is an estimated $245 billion.[4]

For nearly 90 years, BD's culture of innovation and continuous improvement has enhanced the patient experience to help improve therapy and outcomes for people with diabetes worldwide.  BD devices support earlier initiation and better adherence to prescribed therapies to help all diabetes patients live healthier lives.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs